News & Views

Iksuda announces first patient dosed in Phase 1 trial of IKS014

10 January 2022

Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 antibody drug conjugate programme from LegoChem Biosciences

Sign up for more news

Thank you